Intercept pharmaceuticals inc.
The Investor Relations website contains information about Intercept Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
Alfasigma S.p.A. today announced that its wholly-owned subsidiary, Interstellar Acquisition Inc., a Delaware corporation, has commenced a cash tender offer to purchase all of the outstanding ...Apr 13, 2023 · MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ... Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases ...MORRISTOWN, N.J., June 07, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced initial results from a planned interim analysis of its ongoing …Intercept recognized $68.0 million in net sales in the first quarter 2023 compared to $59.2 million in net sales in the prior year quarter. In the quarter ended March 31, 2023, Intercept recorded ...
Nov 8, 2023 · BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma’s ...
MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that REVERSE, a Phase 3 study evaluating the safety and efficacy of OCA in patients ...
BOLOGNA, Italy and MORRISTOWN, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical …Contact Us For more information call: (844) 782–4278 Corporate Headquarters 305 Madison AvenueMorristown, NJ 07960 T: (646) 747–1000 San Diego Office 3636 Nobel Drive, Suite 475,San Diego, CA 92122 T: 858-652-6800Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases ... About Us Leadership Our executive leadership taps into an expertise in liver health and strong business acumen. SEE WHO’S WHO Jerome Durso, Chief Executive Officer & …Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.42. The biopharmaceutical company had revenue of $83.70 million for the quarter, compared to …
Nareg Sagherian, Executive Director, Global Investor Relations. [email protected]. For media: Karen Preble, Executive Director, Global Corporate Communications. media@interceptpharma ...
Hayward Pool Products Inc is a leading manufacturer of high-quality pool equipment, including pumps, filters, heaters, and cleaners. If you’re lucky enough to own one of their products, it’s important to keep it in good condition to ensure ...
Intercept Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 22-3868459 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 10 Hudson Yards, 37th Floor New York, NY 10001 (Address of Principal Executive Offices and Zip Code) (646) 747-1000The most common side effects of OCALIVA include: tiredness; stomach pain and discomfort; rash; joint pain; mouth and throat pain; dizziness; constipation; swelling in your hands, ankles, or feet; fast or irregular heartbeat; fever; changes in how your thyroid gland works; dryness, irritation, redness, crusting or drainage of the skin (eczema).Save hours of research time and resources with our up-to-date Intercept Pharmaceuticals Inc Strategy Report; Understand Intercept Pharmaceuticals Inc position in the market, performance and strategic initiatives. Gain competitive edge and increase your chances of …Contact Email [email protected]. Phone Number +1 646 747 1000. Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with ...Intercept Pharmaceuticals, Inc. revenue from 2013 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry.
NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the fourth quarter and full year ended on December 31, 2021.The company inked the buyout after two FDA rejections for Ocaliva in NASH-related liver fibrosis and a recent attempt at cutting costs.১৯ আগ, ২০২২ ... Intercept Pharmaceuticals Inc. has said it entered into a settlement agreement with Dr. Reddy's Laboratories resolving the previously ...MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...(Pelabuhan Batu Ampar. Dok.Foto: infopublik) Sebagai otoritas pengelola Pelabuhan Batu Ampar, BP Batam melalui Badan Usaha Pelabuhan terus …
Intercept Pharmaceuticals, Inc. December 23, 2022 at 7:50 AM · 4 min read NDA supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 ...
Jan 19, 2023 · MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted Intercept’s New Drug ... NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the Ocaliva (obeticholic acid or OCA) Prescribing Information in the United States has ...Apr 13, 2023 · MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2023 financial results on Thursday, April 27, 2023, and provide an update on the commercial launch strategy for ... Director. Mark Pruzanski, M.D. is one of our co-founders and has served as a member of our Board of Directors since inception in 2002. Dr. Pruzanski served as Intercept’s President and Chief Executive Officer until 2021. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting. MORRISTOWN, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced a restructuring to strengthen the Company’s focus on rare and serious liver diseases and significantly reduce operating expenses, including discontinuing all nonalcoholic steatohepatitis (NASH)-related investment.May 5, 2022 · MORRISTOWN, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced it has entered into an agreement to sell to Advanz Pharma, a pharmaceutical company ... Learn more about ongoing Intercept-sponsored clinical trials below. Primary biliary cholangitis (PBC) Intercept has two ongoing Phase 2 studies, 747-213 and 747-214, that are designed to explore a range of therapeutic doses for the combination of OCA and bezafibrate. Study 747-213 is for patients outside of the United States. Study 747-214 is for patients … ContinuedTracfone Wireless Inc is one of the leading wireless communication providers in the United States. With a wide range of affordable plans and extensive coverage, Tracfone has garnered a loyal customer base over the years.১১ অক্টো, ২০২৩ ... Alfasigma S.p.A. Tender Offer for Intercept Pharmaceuticals, Inc. Commences ... (NASDAQ: ICPT) (“Intercept”) for a price of USD $19.00 per share, ...
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...
Director. Keith Gottesdiener, M.D. has served as a member of our Board of Directors since July 2016. Since July 2020, Dr. Gottesdiener has served as the President and Chief Executive Officer and as a director of Prime Medicine, Inc., a biopharmaceutical company based in Cambridge, Massachusetts. Prior to that, from October 2011 until March 2020 ...
Jan 19, 2023 · MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ... Nov 8, 2023 · BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of ... Intercept Pharmaceuticals, Inc.ICPT announced that the Gastrointestinal Drugs Advisory Committee (GIDAC) of the FDA will discuss the company’s new drug application (NDA) for obeticholic acid (OCA).To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or ...Nareg Sagherian, Executive Director, Global Investor Relations. [email protected]. For media: Karen Preble, Executive Director, Global Corporate Communications. media@interceptpharma ...Intercept Pharmaceuticals (NASDAQ:ICPT) is a biopharmaceutical company focused on developing and marketing innovative treatments for progressive liver diseases that are not caused by viruses.MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...Sep 26, 2023 · Item 1.01 Entry into a Material Definitive Agreement. Agreement and Plan of Merger On September 26, 2023, Intercept Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Alfasigma S.p.A. (“Alfasigma”) and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (“Purchaser”). MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...
To report SUSPECTED ADVERSE REACTIONS, contact Intercept Pharmaceuticals, Inc. at 1-844-782-ICPT or FDA at 1-800-FDA-1088 or ...Item 1.01 Entry into a Material Definitive Agreement. Agreement and Plan of Merger On September 26, 2023, Intercept Pharmaceuticals, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Alfasigma S.p.A. (“Alfasigma”) and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (“Purchaser”).Pipeline - Intercept Pharmaceuticals Home > Our Research > Pipeline Our Pipeline Our portfolio is based on novel scientific targets with the potential for therapeutic application …Instagram:https://instagram. can u pre order the iphone 15prop fundtradebot cryptoamerican airlines stock forecast Dec 23, 2022 · MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug ... Our Pipeline. Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases, with a focus on those with high unmet need. We are leveraging our decades of research and background in bile acids and FXR agonism to expand our pipeline to deliver effective treatments for the growing ... does webull accept itinbnox MORRISTOWN, N.J., June 22, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter ...Contact Us For more information call: (844) 782–4278 Corporate Headquarters 305 Madison AvenueMorristown, NJ 07960 T: (646) 747–1000 San Diego Office 3636 Nobel Drive, Suite 475,San Diego, CA 92122 T: 858-652-6800 international share brokers MORRISTOWN, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) today announced a restructuring to strengthen the Company’s focus on rare and serious liver diseases and significantly reduce operating expenses, including discontinuing all nonalcoholic steatohepatitis (NASH)-related investment.Director. Mark Pruzanski, M.D. is one of our co-founders and has served as a member of our Board of Directors since inception in 2002. Dr. Pruzanski served as Intercept’s President and Chief Executive Officer until 2021. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting.